Statement of Changes in Beneficial Ownership (4)
March 01 2017 - 3:36PM
Edgar (US Regulatory)
|
FORM 4
[
X
]
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue.
See
Instruction 1(b).
|
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
|
OMB APPROVAL
OMB Number:
3235-0287
Estimated average burden
hours per response...
0.5
|
|
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
|
|
|
1. Name and Address of Reporting Person
*
PAPPAS ARTHUR M
|
2. Issuer Name
and
Ticker or Trading Symbol
CoLucid Pharmaceuticals, Inc.
[
CLCD
]
|
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
__
X
__ Director
__
X
__ 10% Owner
_____ Officer (give title below)
_____ Other (specify below)
|
|
(Last)
(First)
(Middle)
C/O COLUCID PHARMACEUTICALS, INC., 222 THIRD STREET
|
3. Date of Earliest Transaction
(MM/DD/YYYY)
3/1/2017
|
|
(Street)
CAMBRIDGE, MA 02142
(City)
(State)
(Zip)
|
4. If Amendment, Date Original Filed
(MM/DD/YYYY)
|
6. Individual or Joint/Group Filing
(Check Applicable Line)
___ Form filed by One Reporting Person
_
X
_ Form filed by More than One Reporting Person
|
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
|
1.Title of Security
(Instr. 3)
|
2. Trans. Date
|
2A. Deemed Execution Date, if any
|
3. Trans. Code
(Instr. 8)
|
4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
|
5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4)
|
6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)
|
7. Nature of Indirect Beneficial Ownership (Instr. 4)
|
|
Code
|
V
|
Amount
|
(A) or (D)
|
Price
|
|
Common Stock
|
3/1/2017
|
|
U
|
|
1871049
|
D
|
$46.50
(1)
|
0
|
I
|
By A. M. Pappas Life Science Ventures III, L.P.
(2)
|
|
Common Stock
|
3/1/2017
|
|
U
|
|
116317
|
D
|
$46.50
(1)
|
0
|
I
|
By PV III CEO Fund, L.P.
(3)
|
|
Common Stock
|
3/1/2017
|
|
U
|
|
5528
|
D
|
$46.50
(1)
|
0
|
I
|
By Pappas Capital, LLC
(4)
|
Table II - Derivative Securities Beneficially Owned (
e.g.
, puts, calls, warrants, options, convertible securities)
|
1. Title of Derivate Security
(Instr. 3)
|
2. Conversion or Exercise Price of Derivative Security
|
3. Trans. Date
|
3A. Deemed Execution Date, if any
|
4. Trans. Code
(Instr. 8)
|
5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
|
6. Date Exercisable and Expiration Date
|
7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4)
|
8. Price of Derivative Security
(Instr. 5)
|
9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)
|
10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)
|
11. Nature of Indirect Beneficial Ownership (Instr. 4)
|
|
Code
|
V
|
(A)
|
(D)
|
Date Exercisable
|
Expiration Date
|
Title
|
Amount or Number of Shares
|
|
Stock Option (Right to Buy)
|
$10.00
|
3/1/2017
|
|
D
|
|
|
5954
|
(5)
|
5/5/2025
|
Common Stock
|
5954
|
$36.50
|
0
|
D
|
|
|
Stock Option (Right to Buy)
|
$6.24
|
3/1/2017
|
|
D
|
|
|
8897
|
(6)
|
5/10/2026
|
Common Stock
|
8897
|
$40.26
|
0
|
D
|
|
|
Explanation of Responses:
|
|
(
1)
|
Pursuant to the terms of the Agreement and Plan of Merger, dated January 17, 2017 (the "Merger Agreement"), by and among CoLucid Pharmaceuticals, Inc. (the "Issuer"), Eli Lilly and Company ("Lilly") and ProCar Acquisition Corporation, a wholly-owned subsidiary of Lilly, these shares were tendered pursuant to the Merger Agreement in exchange for a cash payment of $46.50 per share in cash, without interest.
|
|
(
2)
|
Represents securities held directly by A.M. Pappas Life Science Ventures III, L.P. AMP&A Management III, LLC is the general partner of A. M. Pappas Life Science Ventures III, L.P. and has a management agreement with Pappas Capital, LLC (fka A. M. Pappas & Associates, LLC) ("Pappas Capital"). As a result, Pappas Capital's investment committee has sole power to vote or to direct the vote of, and sole power to dispose or to direct the disposition of, all shares owned A.M. Pappas Life Science Ventures III, L.P. The reporting person is the sole managing member of Pappas Capital. The reporting person may be deemed to be an indirect beneficial owner of the reported securities. The reporting person disclaims any beneficial ownership of the reported securities, except to the extent of any pecuniary interest therein. This report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose.
|
|
(
3)
|
Represents securities held directly by PV III CEO Fund, L.P. AMP&A Management III, LLC is the general partner of PV III CEO Fund, L.P. and has a management agreement with Pappas Capital. As a result, Pappas Capital's investment committee has sole power to vote or to direct the vote of, and sole power to dispose or to direct the disposition of, all shares owned PV III CEO Fund, L.P. The reporting person is the sole managing member of Pappas Capital. The reporting person may be deemed to be an indirect beneficial owner of the reported securities. The reporting person disclaims any beneficial ownership of the reported securities, except to the extent of any pecuniary interest therein. This report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose.
|
|
(
4)
|
Represents securities held directly by Pappas Capital. The reporting person is the sole managing member of Pappas Capital. The reporting person may be deemed to be an indirect beneficial owner of the reported securities. The reporting person disclaims any beneficial ownership of the reported securities, except to the extent of any pecuniary interest therein. This report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose.
|
|
(
5)
|
Pursuant to the terms of the Merger Agreement, these options, which were fully vested, were cancelled in exchange for a cash payment of $46.50 less the per share exercise price multiplied by the number of unexercised options, without interest.
|
|
(
6)
|
Pursuant to the terms of the Merger Agreement, these options, which provided for full vesting immediately prior to the start of the Issuer's first annual meeting of stockholders following the date of grant, were cancelled in exchange for a cash payment of $46.50 less the per share exercise price multiplied by the number of unexercised options, without interest.
|
Reporting Owners
|
|
Reporting Owner Name / Address
|
Relationships
|
|
Director
|
10% Owner
|
Officer
|
Other
|
PAPPAS ARTHUR M
C/O COLUCID PHARMACEUTICALS, INC.
222 THIRD STREET
CAMBRIDGE, MA 02142
|
X
|
X
|
|
|
A.M. Pappas Life Science Ventures III, L.P.
2520 MERIDIAN PARKWAY, SUITE 400
DURHAM, NC 27713
|
|
X
|
|
|
PV III CEO Fund, L.P.
2520 MERIDIAN PARKWAY, SUITE 400
DURHAM, NC 27713
|
|
X
|
|
|
PAPPAS CAPITAL, LLC
2520 MERIDIAN PARKWAY, SUITE 400
DURHAM, NC 27713
|
|
X
|
|
|
Signatures
|
|
/s/ Christine G. Long, Attorney-in-Fact for Arthur M. Pappas (power of attorney previously filed)
|
|
3/1/2017
|
|
**
Signature of Reporting Person
|
Date
|
|
/s/ Christine G. Long, Attorney-in-Fact for A.M. Pappas Life Science Ventures III, L.P. (power of attorney previously filed)
|
|
3/1/2017
|
|
**
Signature of Reporting Person
|
Date
|
|
/s/ Christine G. Long, Attorney-in-Fact for PV III CEO Fund, L.P. (power of attorney previously filed)
|
|
3/1/2017
|
|
**
Signature of Reporting Person
|
Date
|
|
/s/ Christine G. Long, Attorney-in-Fact for Pappas Capital, LLC (power of attorney previously filed)
|
|
3/1/2017
|
|
**
Signature of Reporting Person
|
Date
|
|
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
|
|
*
|
If the form is filed by more than one reporting person,
see
Instruction 4(b)(v).
|
|
**
|
Intentional misstatements or omissions of facts constitute Federal Criminal Violations.
See
18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
|
|
Note:
|
File three copies of this Form, one of which must be manually signed. If space is insufficient,
see
Instruction 6 for procedure.
|
|
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.
|
COLUCID PHARMACEUTICALS, INC. (NASDAQ:CLCD)
Historical Stock Chart
From Apr 2024 to May 2024
COLUCID PHARMACEUTICALS, INC. (NASDAQ:CLCD)
Historical Stock Chart
From May 2023 to May 2024
